Already a member? Sign in
Strattera® is a brand name for the drug atomoxetine HCL, a selective norepinephrine reuptake inhibitor used in the treatment of attention deficit hyperactivity disorder (ADHD).
| Purpose | # of patients |
# of patients with evaluations
Efficacy
|
Major | Moderate | Slight | None | Can’t tell |
|---|---|---|---|---|---|---|---|
| ADHD (Attention Deficit/Hyperactivity Disorder) | 43 | 12 |
|
|
|
|
|
| Problems concentrating | 20 | 7 |
|
|
|
|
|
| Other | 15 | 4 |
|
|
|
|
|
| Depressed mood | 7 | 1 |
|
||||
| Treat my mood condition(s) | 6 | 2 |
|
||||
| ADD (Attention Deficit Disorder) | 5 | 2 |
|
See all 65 patients currently taking Strattera
Mouse over the table for more information
Commonly reported side effects, conditions, and hospitalizations associated with Strattera
| Constipation | 6 | |
|---|---|---|
| Nausea | 5 | |
| Elevated blood pressure | 3 | |
| Loss of appetite | 3 | |
| Drowsiness | 2 | |
| Tension | 2 | |
| See all 30 reported side effects ▼ | ||
Frequently reported dosages based on patients currently taking Strattera. See all 12 dosages ►
| Reason | # Patients | Percentage of patients | |
|---|---|---|---|
| Did not seem to work | 22 | ||
| Side effects too severe | 21 | ||
| Other | 10 | ||
| Doctor's advice | 9 | ||
| Expense | 5 | ||
| Course of treatment ended | 2 | ||
| Change in health plan coverage | 2 | ||
| Not indicated | 2 | ||
| Personal research | 1 |
Adherence
Taking treatment as prescribed
Adherence of Strattera
Always |
19 | 59% |
|
|---|---|---|---|
Usually |
11 | 34% |
|
Sometimes |
2 | 6% |
|
Never |
0 | 0% |
|
Burden
Difficulty being on treatment
Burden of Strattera
Very |
1 | 3% |
|
|---|---|---|---|
Somewhat |
6 | 19% |
|
A little |
8 | 25% |
|
Not at all |
17 | 53% |
|
Cost
Paid out of pocket
Cost of Strattera
$200+ |
0 | 0% |
|
|---|---|---|---|
$100-199 |
1 | 6% |
|
$50-99 |
4 | 25% |
|
$25-49 |
8 | 50% |
|
< $25 |
3 | 19% |
|
See more information, including instructions, precautions, side effects, and interactions.
Report created on February 10, 2012.